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                                                                  ABSTRACT 
ESTIMATION OF HIGH SENSITIVITY C-REACTIVE PROTEIN AND LIPOPROTEIN[a] 
IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 
BACKGROUND: 
                        Chronic obstructive pulmonary disease remains the second most common disorder 
affecting the lungs, next only to pulmonary tuberculosis in India. Recently Hs-CRP measuring 
methods have made it possible to assess this protein even in lower levels of inflammation. Patients 
affected by COPD have an risk of atherothrombotic acute events. Hypercoagulable state is assessed 
by measuring the Lp(a). 
AIMS OF THE STUDY: 
               To study the levels of Hs-CRP and Lp(a) in COPD patients and to assess their correlation  
with the severity of the disease and  the risk of atherosclerotic disease respectively. 
MATERIALS AND METHODS: 
                     Patients with clinically diagnosed and spirometrically confirmed cases of COPD were 
included in the study and classified based on GOLD staging. This was a case-control study with 
sample size of  50 cases and 30 controls, conducted in Chennai medical college hospital and research 
centre during  January 2014 – December  2014. Serum Hs-CRP levels and Lp(a) levels were 
measured by Immunoturbidimetry method. 
RESULTS: 
               The levels of Hs-CRP were significantly elevated in  COPD  patients. There exists a 
positive correlation with severity of the disease, obese individuals and smokers. There was no 
association of Hs–CRP levels with age and duration of the disease. Circulating Lp(a)  levels are 
higher in COPD patients may thus be regarded as a valid biomarker of atherothrombotic  acute 
events. There is no association between mean Lp(a) levels and the spirometry staging, BMI, 
smoking, disease duration. 
CONCLUSION: 
               Serum Hs-CRP and Serum Lp(a)  levels may be used as a simple auxiliary marker in 
staging determining the severity and prognosis of  COPD  and in determining the  risk of 
atherosclerotic disease in COPD patients respectively for early intervention. 
Key words:  High sensitivity C-reactive protein, Lipoprotein(a), Chronic Obstructive Pulmonary 
Disease, Immunoturbidimetry, Spirometry, GOLD staging. 
                                         INTRODUCTION 
                 Chronic obstructive pulmonary disease (COPD)  has been defined by the 
global initiative for chronic obstructive lung disease (GOLD- Global initiative of 
Chronic Obstructive Lung Disease)
1
 as  a disease state characterized by air flow 
limitation that is not fully reversible, usually progressive and is associated with an 
abnormal inflammatory response of the lung to inhaled noxious particles or gases. 
chronic obstructive pulmonary disease includes
2,3 
1.EMPHYSEMA: Abnormal permanent enlargement of air spaces distal to the 
terminal bronchioles along with destruction of their walls without any fibrosis. 
2.CHRONIC  BRONCHITIS: Chronic bronchial mucus hyper secretion resulting 
in chronic expectoration ( coughing out of sputum on most days during atleast 3 
consecutive months in 2 successive years). 
3.SMALL  AIRWAY  DISEASE: Narrowing of small bronchioles. 
             GOLD estimates that chronic obstructive pulmonary disease is the 6
th
 most 
common cause of death worldwide
4 
and it is predicted that it will be the 3rd most 
common cause of death in future (2020). 
              In India, after pulmonary tuberculosis , chronic obstructive pulmonary 
disease remains the second most common disorder affecting the lung. 
             Chronic obstructive pulmonary disease is frequently seen in middle aged 
individuals. It is more commonly seen in males due to increased prevalence of 
smoking in our setup. 
              It is equally prevalent both in rural and urban areas. Increasing 
urbanization and emergence of industries leading to air pollution and increased 
smoking among young people may have definite impact on the incidence of chronic 
obstructive pulmonary disease. 
              Some of the predisposing factors in childhood for development of chronic 
obstructive pulmonary disease in future includes low birth weight, malnutrition and 
recurrent respiratory tract infection.  
              In patients with Chronic obstructive pulmonary disease the most robust test 
in assessing the air flow limitation is the spirometry.
5 
  
             A low FEV1 (FEV1< 80%) with FEV1/FVC ratio less than 0.7 and less 
than 15% reversibility of airflow obstruction post bronchodilator therapy is the 
diagnostic criteria for chronic obstructive pulmonary disease. 
            
 
With the wide spread use of spirometry, identification of air flow 
obstruction is considered as a key factor in determining the disability of  chronic 
obstructive pulmonary disease patients.
 
             Patients with chronic obstructive pulmonary disease will experience a 
systemic inflammation. It is assessed by measuring the inflammatory mediators like 
C reactive protein. 
            Recently high sensitivity C-reactive protein (Hs-CRP) measuring methods 
have made it possible to assess this protein even in lower levels of inflammation. 
             
 
  
                 Chronic obstructive pulmonary disease patients have an increased risk of 
atherothrombotic acute events, independent of smoking and other cardiovascular 
risk factors. 
                 Bronchial inflammation spreads to the systemic circulation and is known to 
play a key role in plaque formation and rupture. 
                 Systemic inflammation is the first common cause of the hypercoagulable 
state observed in copd
6
.  
                Hypercoagulable state is assessed by measuring the lipoprotein(a).  
 
 
 
 
 
 
 
 
 
 
 
                               AIMS OF THE STUDY 
1. To estimate  the  level of  High Sensitivity C-reactive Protein in patients with 
Chronic Obstructive Pulmonary Disease. 
2. To  estimate  the  level  of  Lipoprotein[a]   in patients with Chronic Obstructive 
Pulmonary Disease. 
                        OBJECTIVES OF THE STUDY 
1. To assess the correlation of High Sensitivity C-reactive Protein levels with various 
stages of COPD. 
2. To evaluate the correlation of Hs-CRP in COPD patients with respect to other 
variables such as age, sex, smoking habits and disease duration. 
3. To assess the correlation of smoking habits with severity of disease. 
4. To assess the correlation of BMI levels with severity of disease. 
5. To assess the correlation of Lipoprotein(a)  levels with Lipid profile. 
6. To prove the use of Hs-CRP in determining the severity of COPD and better control 
of disease prognosis. 
7. To prove the use of Lipoprotein(a) in determining  the  risk  of  atherosclerotic disease in 
COPD patients. 
 
                
                           REVIEW OF LITERATURE 
             From the time of Laennec., et al throughout the first half of the 20
th
 
century, mechanical explanations of chronic obstructive pulmonary disease 
dominate. 
            As early as in 1905 OPIE et al., suggested that serine proteases and 
antiproteases imbalance plays an important role in pathophysiology of emphysema. 
            In 1956 Medical council of research first used the terminology chronic 
bronchitis in patients with chronic cough with sputum production. 
            In 1959 the causal relation between the smoking and persistent cough with 
expectoration was explained by Higgins.,et al. 
           In 1960 Owen and Campbell et al., observed the pathological changes in 
airway due to cigarette smoking. 
           In 1973 Boughly et al,. submitted a list of articles related to prognostic 
factors in COPD and importance of pulmonary function test in these patients. 
           In 2007 Sanjamarevic et al.,
61  
concluded that levels of  high sensitivity C-
reactive protein were significantly higher in patients with COPD and hence proved 
that it will be a more sensitive marker than TNF alpha, CXCL-8 and big ET 1 in 
systemic circulation. 
             
 
            Daianastolz et al.,
67 
in 2007 analysed the levels of copeptin, C-reactive 
protein, procalcitonin in acute exacerbation of COPD patients and all are found to 
be significantly elevated. 
           Yannick MTA et al.,
63 
from Erasmus university in 2008 observed the 
predictive role of high sensitivity C-reactive protein for COPD in smokers. 
           In 2008-2009 SAAlavi et al.,
62 
from  Guilan university, Iran found a 
correlation between the levels of high sensitivity C-reactive protein based on the 
GOLD staging of COPD. 
           Bridevaux et al.,
66 
in 2009 in his SAPALDIA cohort study (swiss study on 
air pollution and lung diseases in adults) correlated the elevated levels of high 
sensitivity C-reactive protein in association with fast decline of FEV1 and obese 
patients. 
           In 2010 Lisa Tileman et al.,
60 
from Germany identified the distinct aspects 
of systemic inflammation in bronchial asthma and COPD by measuring the levels of 
high sensitivity C-reactive protein (significantly elevated in COPD) and IgE, blood 
eosinophils, fractional exhaled nitric oxide levels (elevated in bronchial asthma). He 
also suggested that these markers have replaced the role of spirometry when not 
available. 
           
 
 
  
 
           Jack et al.,
68  
in 2010 concluded that levels of high sensitivity C-reactive 
protein and surfactant protein D levels are higher in acute exacerbation of COPD 
which indicates the infectious state in our body. So it can also be used as a guide in 
the treatment of acute exacerbation of COPD. 
           Recent study conducted in Maulana Azad medical college in New Delhi 
correlated the levels of Hs-CRP as a marker of functional disability in COPD 
patients. 
           Filippo Luca Fimognari et al
6
., in 2008 identified the mechanisms of 
atherothrombosis  in chronic obstructive pulmonary disease. Systemic inflammation 
plays a leading role in atherosclerotic plaque formation and rupture, but other 
mechanisms, such as platelet activation, coagulation and oxidative stress, can 
promote atherosclerosis in COPD. 
          Stephan Van Eeden  et al.
56
., in 2012  identified the relationship between 
lung inflammation and cardiovascular disease. Acute and chronic lung inﬂammation 
is an under recognized risk factor for cardiovascular disease. There are compelling 
epidemiological data to indicate that airway exposures to cigarette smoke, air  
 
 
 
 pollution particles, viral and bacterial pathogens are strongly related to acute 
ischemic events. This article, reviewed  the epidemiological data for the relationship 
between lung inflammation and cardiovascular disease and provide plausible 
mechanistic pathways by which acute and chronic inﬂammation contributes to the 
development of acute cardiovascular syndromes. 
           Archana Burman A
1
, et al
57  
identified Lipoprotein(a) as a marker of 
coronary artery disease and its association with dietary fat. This study confirms that 
though TC, TG and LDL-C are important risk factors for CAD, Lipoprotein(a) 
shows a stronger association with CAD than these lipids. Hence Lipoprotein(a) may 
prove to be a better discriminator of CAD risk at an early age since its levels are 
alleged to be genetically determined.  
            Fauzia Ashfaq, et al 
58  
identified Lipoprotein(a) levels in relation to the 
severity of coronary artery disease in North Indian patients. 
This study confirms the necessity of Lipoprotein(a) and other risk factors to predict 
the severity of coronary atherosclerosis, suggesting that Lipoprotein(a) levels 
should be determined in patients with CAD, especially in normolipidemic 
individuals. 
 
 
 
                 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
                  It is a preventable and treatable condition characterized by progressive air 
flow limitation that is not fully reversible. It includes a group of conditions that 
occurs due to pathological changes in large and small airways as well as lung 
parenchyma. It is due to abnormal inflammatory response in lungs to inhaled 
noxious particles and gases. 
                 In clinical practice , the diagnosis of COPD should be thought in patients 
above 35yrs of age, those with chronic progressive symptoms (cough, wheeze, 
breathlessness) and other risk factors such as cigarette smoking and occupational or 
environmental dusts or gases. 
Prevalence in India: 
                 In males the prevalence rate is 2.12 to 9.4% in North India compared to 
1.4 - 4.08% in South India.
7,8. 
In females the prevalence is less which is about      
1.3-4% from North India and 22.5-2.7 % in South India.
9
 In general the male female 
ratio is about 1.6:1.0 
COPD and its comorbidities: 
1. Diabetes 
2. Ischemic Heart Disease 
3. Depression 
4. Osteoporosis 
5. Weight Loss 
6. Peptic Ulcer Disease 
7. Glaucoma 
Natural history and prognosis:
10,11,12 
             FEV1 declines at a rate of 20-30ml/hour in non-smokers, whereas in 
smokers the decline rate will be more than 50ml/hour. FEV1 is a strong predictor of 
survival. Only less than 50% of patients whose FEV1 less than 30% may survive 5 
years and above. Recent studies showed that the BODE index which includes 
FEV1, dyspnea, body weight, 6 minutes walk test are important in predicting the 
prognosis than FEV1 alone. 
RISK FACTORS: 
Smoking: 
               Most commonly identified correlate with chronic bronchitis is cigarette 
smoking. The mortality rate varies with the dose response curve with pack years of 
smoking.
13 
When compared to nonsmokers, there is a 25% increase in mortality in 
smokers. The mortality in pipe and cigar smokers is lower than the cigarette 
smokers. Filter tip cigarettes are comparably less harmful. 
 
             Incidence of the disease decreases if smoking is stopped early in the course 
of the disease.
14,15  
Cessation of smoking do not normalize the lung functions, 
instead it slows down the deterioration. 
             
 
              In males the loss of FEV1 in excess of normal decline with aging is 9ml per 
year for each pack year of smoking. In females, the rate of decline in FEV1 is 6ml.
16 
             Prolonged smoking impairs the ciliary motility, macrophages accumulate in 
higher quantities in respiratory bronchioles  which in turn releases proteinases and 
is responsible for destruction of extracellular matrix of lung. These macrophages 
recruit chemotactic  factors which in turn attracts other inflammatory cells to lung 
and causes mucus gland hyperplasia. Cigarette smoke inhibits anti proteases and 
releases proteolytic enzymes, thereby destroying the alveolar wall.
17
 
             Passive smoking otherwise called as environmental tobacco smoke 
exposure
18,19
 plays an important role in nonsmokers particularly among the women. 
Air pollution: 
              Pollutants for air pollution includes exhausts from automobiles, industries 
and factories.
20,21,22 
 Smoke from solid fuel combustion such as dried dung, wood 
crop residues used in cooking in villages and slum areas also contributes to major 
source of air pollution in developing countries like India
23,24
.
 
Occupation : 
              According to American thoracic society the occupational contribution to the 
burden of COPD is around 15%.
25,26 
  Various studies from all over the world 
quoted that occupation involving exposure to dust, gases, fumes as a major 
contributing factor to COPD. Chronic bronchitis is more prevalent among workers  
 
 exposed to organic or inorganic dusts. Occupational hazards include exposure to 
cadmium, toluene gas in plastic plants, construction and utility work.
 
Recurrent respiratory tract infections: 
                Lower respiratory infections in childhood is also postulated as a risk factor 
for the development of COPD.
27,28,29  
This is due to the permanent damage or 
impaired lung growth. The risk of reduced lung function in future is high. 
Airway hyper responsiveness: 
              Many patients with COPD also experiences airway 
hyperresponsiveness
30,31,32  
which is a common association in bronchial asthma. The 
rate of reversibility in the degree of obstruction with bronchodilators is less than  
15 %. 
GENETIC BACKGROUND: 
               Aggregation of cases in families suggest that there is an established role for 
genetic factors in the pathogenesis of COPD. Occurrence of early onset COPD and 
decrease in the maximal expiratory flow rate among the nonsmoking first degree 
relatives of COPD supports the above said statement.  
              Polymorphism of genes involving protease – antiprotease  balance, 
antioxidant function, inflammation and immune responses has been proposed. 
              
 
            Alpha 1 antitrypsin is a major antiprotease enzyme in the serum.
33 
The 
synthesis of alpha one antitrypsin is regulated by a gene on chromosome 14q32.
 
The 
most common deficient allele is PiZZ phenotype which is due to amino acid 
substitution of 342 Glutamic  acid to lysine.
34 
            This change results in spontaneous polymerization of polypeptide and 
impaired release of alpha one antitrypsin from the liver. This deficiency is rare in 
Asian and African descendants, whereas more common in European population     
(1 in 2000 to 1 in 7000). About 2 % of the patients with emphysema is due to alpha-
1 antitrypsin deficiency.
35
 
           Patients usually presents with premature bronchiectasis or chronic bronchitis. 
More than 80 percent of the patients have autosomal recessive inheritance. Decline 
in FEV1 is around 100-130ml per year for smokers ,50-80ml per year for 
exsmokers and nonsmokers. 
             Panacinar emphysema is the most common type seen with predominant 
involvement of lower lobes of the lung. Smoking is an important cofactor in the 
development of COPD in patients with alpha one antitrypsin deficiency. They are 
also at an increased risk for cirrhosis of liver. 
 
 
 
  
PATHOLOGY: 
                Pathological changes are seen in larger and smaller airways as well as 
  in terminal bronchioles. Small airways are considered as important site of airflow 
limitation.
36,37 
Various reasons which are responsible for narrowing of lumen of 
small airways are goblet cell hyperplasia, edema, mucosal and submucosal 
inflammatory cells, peribronchial fibrosis, smooth muscle hypertrophy and mucus 
plugs.
38 
                In larger airways hypertrophy of submucosal mucous glands is seen. Reid 
index is a measure of thickness of submucous glands to that of bronchial wall . In 
normal individuals the range is between 0.44 to 0.60, whereas in chronic bronchitis 
it is between 0.34 -0.53. 
               Emphysema starts as an increase in both number as well as size of the 
alveolar fenestrations and results in destruction of the septa. It also destroys the 
attachments of the septa to the terminal bronchioles. The site of destruction varies in 
different types of emphysema. In centriacinar it predominantly involves respiratory 
bronchioles, whereas panacinar involves both central as well as peripheral 
bronchioles. 
 
 
 PATHOGENESIS AND PATHOPHYSIOLOGY: 
                Central to the pathogenesis is found to be an enhanced inflammatory 
process in response to inhaled particles and gases.
39,40   
The pathogenesis includes 
various processes 
           1. Increased airway inflammation
41 
           2. Increased protease burden-decreased anti protease function
42 
           3. Oxidant –anti oxidant imbalance (oxidative stress) 
           4. Defective lung repair mechanisms 
        Chronic exposure to smoke, fumes, dusts results in inflammatory recruitment of 
inflammatory cells within the terminal air space of lungs. These cells results in 
destruction of walls and extra cellular matrix of the lungs. 
         Persistent reduction in the forced expiratory flow is the defining feature in case 
of  COPD. 
Other typical features are 
1. Increased airway resistance 
2. Increased residual volume 
3. Increased RV/TLC 
4. Decreased inspiratory capacity 
5. Maldistribution of ventilation. 
 
 Airflow obstruction: 
            Balance between the elastic recoil of the lungs that promote the flow and the 
resistance of airway that limits the flow contribute to the airflow during forced 
exhalation. 
           As the cross sectional area of the airway falls due to destruction the resistance 
increases, and the expiratory flow also decreases as the volume occupied decreases 
due to loss of elastic recoil and loss of radial traction of airways.  In early stages the 
abnormality in airflow limitation is seen only at lung volumes at or below the FRV. 
           It is possible to distinguish between emphysema and small airway pathology 
only theoretically, since emphysema is due to decreased elastic recoil and small 
airway disease is due to increased airway resistance as a cause of reduced FEV1. 
Clinically it is more difficult to differentiate between these two as it co exist in most 
of the patients. 
           FEV1 correlation is better with small airway pathology when compared to 
emphysema.  FEV1 remains a good predictor because PaO2 usually remains near 
normal till FEV1 decreases up to half of the predicted level. Very low levels of 
FEV1 can be still associated with normal PaO2. Usually PaCO2 is not elevated until 
the FEV1 is less than 25% of  predicted value. 
 
 
 
  
Maldistribution of ventilation: 
           COPD is a heterogenous disease, since it affects both airways as well as lung 
parenchyma. This heterogeneity can be revealed by xenon gas ventilation. 
MIGET classification of COPD: 
           Type A- high ventilation perfusion ratio-emphysema 
           Type B-low ventilation perfusion- chronic bronchitis 
          But most of the COPD patients will have neither type A or B, they will have 
both high and low perfusion areas. The reduction of PaO2 is mainly due to 
Ventilation/Perfusion mismatch, shunt is minimal. So moderate concentration of O2 
can correct the hypoxemia in COPD. If it is not getting corrected then other causes 
such as pulmonary embolism, shunting should be considered. 
Hyperinflation: 
It is defined as 
1. increased FRV. 
2. increased residual volume to total lung capacity. 
3. decreased inspiratory capacity to total lung capacity. 
 
 
 
 
 Though hyperinflation may be some times beneficial, adverse effects are more. 
             The adverse effects are due to 
             1. Loss of apposition zone,between the diaphragm and abdominal wall, so 
pressure cannot be transmitted for effective respiration. 
             2. Flattened short diaphragm muscles are not able to generate inspiratory 
pressures. 
             3. Increased tension required to generate transpulmonary pressure. 
In those with hyperinflation the inspiratory capacity will be reduced. 
       Inspiratory capacity can be used as a prognostic significant value independent of 
the FEV1. 
       Recently lung cells senescence has been involved in the pathogenesis of 
emphysema. 
Pathophysiology of exacerbation: 
            Exacerbation of COPD are associated with a further increase in inflammatory 
response in the lungs predominantly involving neutrophils. These response may be 
triggered by bacterial or viral infection or by pollutants. This worsens the existing 
ventilation perfusion mismatch leading to respiratory failure and death. 
 
 
 
  
Lesions of the vessels in COPD: 
             There is no specific change in the vessel wall of the patient with COPD, 
sometimes atheromata may be seen. Pulmonary hypertension develops during late 
phase of the disease. These changes are mostly secondary to vascular shunting and 
increased intimal fibrosis. 
Pulmonary circulation in COPD: 
            In later stages of the disease pulmonary arterial hypertension develops, along 
with the development of hypoxemia, hypercapnia. It is the important complication 
of COPD. It is associated with development of right ventricular hypertrophy and 
worse prognosis. 
Abnormal blood gas tension: 
Hypoxemia: 
           Since hypoxemia is a potent vasoconstrictor , PaO2 has an inverse relationship 
with the development of pulmonary arterial hypertension. Increasing arterial 
desaturation worsens the pulmonary pressure. Pulmonary artery pressure rises 
suddenly during REM sleep because of the relative hypoxemia and recurrence of 
this nocturnal pulmonary hypertension is inturn responsible for the changes in 
pulmonary hypertension. 
 
 Hypercapnia: 
          There exists a direct relation with the PaCO2 and pulmonary artery pressure. 
This is probably due to hyperventilation induced hypercapnia or hypoxia induced 
pulmonary hypertension. 
Acidemia: 
          Combination of both hypoxia and hypercapnia results in pulmonary 
hypertension in patients with COPD. So for given PO2 the mean Ppa is higher with 
increasing hydrogen concentration. 
Effects of abnormal pulmonary mechanics: 
          Changes in the pulmonary resistance results from increase in airway resistance 
matching with decrease in FEV1. 
Effects of increased cardiac output: 
           Even minor increments in the cardiac output that occurs during exercise 
significantly rises the pulmonary arterial pressure. 
Effects of blood viscosity: 
           Chronic hypoxemia which in turns develops polycythemia due to increased 
production of erythropoietin contributes to increasing blood viscosity thereby 
increasing pulmonary arterial hypertension. 
 
 
  
Corpulmonale: 
              Corpulmonale is defined as right ventricular hypertrophy and dilatation 
secondary to diseases of  the lung parenchyma/vasculature or both.  The prevalence 
of corpulmonale is higher in patients with hypercapnia,  hypoxemia,  polycythemia   
and in those with reduced FEV1. In clinically stable patients inspite of elevated 
pulmonary arterial pressure the right ventricular contractility is maintained.  
              In contrast, in patients with respiratory failure the right ventricular 
contractility is decreased . Edema in the late stages of the disease may not be 
entirely due to right ventricular failure, other causes should be ruled out. Due to 
hypoxemia and hypercapnia there will be a reduction in the renal function due to 
decreased blood flow which leads to changes in salt water balance. Decreased blood 
flow may be due to inappropriate arginine vasopressin levels or neurally mediated 
catecholamine release. Thus the development of peripheral edema in COPD 
involves a complex hemodynamics with multiple interactions.  
             Other grave risk factors include marked hypoxemia, increased pulmonary 
artery pressure and decrease in carbon monoxide transfer. In patients with right 
ventricular failure , the prognosis will be poor and mortality rate will be high up to 
65-80%.  
 
 INVESTIGATIONS: 
Radiology:  
Chest x-ray:  
            In chronic bronchitis, parallel line opacities are seen which are indicative of 
bronchial wall thickening.
43,44
 
The radiographic features of emphysema includes:  
 Overinflation of the lungs 
 Low flattened diaphragm - the border of diaphragm lies below the 7th  rib.  
 Height of the lung is greater than 30 cm 
 An obtuse costophrenic angle may be seen. 
 Vertical and narrowed heart shadow is seen (tubular heart).  
 Reduction in size and number of pulmonary vessels in the periphery of the lung.  
 Hilar vessels are enlarged. 
 In lateral chest x-ray there is an increase in the retrosternal  space (>2.54 cm).  
 Presence of bullous lesions is an important evidence of emphysema.  
                  Bullae may present as a stable lesion. Sometimes, it may enlarge 
massively sufficient enough to cause the collapse of the entire lung. It is called as 
vanishing lung syndrome. Pneumothorax is the important  differential diagnosis. 
Bullae may rupture to produce secondary  pneumothorax.  
 
  In fluoroscopy , low and flat diaphragm is seen. A paradoxical upward movement 
during inspiration may be noted.  
Computed tomography:  
                 It  has greater sensitivity and specificity in the diagnosis of emphysema 
when compared to chest x-ray.
45,46  
It is helpful in the evaluation of  bullous lesions 
of the lung. It is seen as areas of low attenuation without Obvious margins.       
Attenuation and pruning of the vessels can be detected.  
                 A decrease in the CT lung density signifies the presence of  microscopic 
emphysema.  
                 Bronchograms may show irregular, narrowed and distorted bronchi. 
Spirometry :
47 
             It is the most important test in assessing the air flow limitation. It is helpful 
in arriving at a diagnosis of COPD and also in predicting the severity of the disease 
and in further follow up of patients. 
             The major abnormalities include reduction in FEV1 and in the ratio of 
FEV1/FVC . 
             The presence of a post bronchodilator FEV1 <80% along with FEV1/FVC 
ratio <0.7 indicates the presence of airflow obstruction that is not totally reversible. 
             
 
 
  
 Assessment of reversibility to bronchodilators is done in COPD patients to 
differentiate it from bronchial asthma . It is also important in identifying the post 
bronchodilator FEV1 which is a better predictor of the prognosis. 
             According to ATS and GOLD guidelines a change in FEV1 of more than 
200 ml and a percentage change of more than 12% is considered as significant 
reversibility but according to British thoracic society guidelines change in FEV1 
50% above the base line is considered significant. 
            Around 30% of COPD patients may show significant reversibility with 
bronchodilator therapy. 
Arterial blood gas analysis: 
            Useful in assessing degree of hypoxemia and hypercapnia. 
                        Usually seen once FEV1< 50% 
             Blood gas abnormalities may occur during exercise and sleep and during 
exacerbations. 
             Though pulse oximetry is commonly used , it is not to be considered as a 
replacement for ABG. 
 
 
 
 CRP an inflammatory marker: 
              Inflammation is considered as a protective response of vascular connective 
tissue to external injury or stimuli . It is usually associated with the release of 
inflammatory mediators like prostanoids, vasoactive amines, cytokines and reactive 
oxygen species. 
              The term acute phase response (APR)
48
 is described to encompass all the 
changes occurring in various organs in response to systemic inflammation. It is a 
non specific response initiated by various stimuli like burns, surgical or physical 
trauma, irradiation and infection. Cytokines mediating this acute phase response are 
stumour necrosis factor alpha, interleukin 1 and interleukin 6 . One of the most 
fascinating fact of the APR is rise in acute phase proteins synthesized in the liver. 
Acute phase proteins: 
Positive acute phase proteins: 
1.Protease inhibitors such as anti chymotrypsin and alpha 1 anti trypsin 
2.Coagulation proteins such as fibrinogen, plasminogen, prothrombin and   factor 
VIII. 
3.Various complement proteins such as C2,C3,C4,C5,C1esterase inhibitor and 
plasminogen. 
 
 
  
4.Transport and storage proteins such as haemopexin, ceruloplasmin, ferritin and 
haptoglobin. 
5.Other positive APR „s are CRP, procalcitonin, serum fibronectin, alpha1 acid 
glycoprotein (orosomucoid), mannose binding lectin and serum amyloid protein. 
Negative acute phase proteins: 
1. Albumin 
2. Pre albumin 
3. Transthyretin 
4. Transcortin 
5. Transferrin 
6. Antithrombin 
               CRP is a biological substance which was known as acute phase reactant for 
long back, originally described 70 years ago . Now it is used as an inflammatory 
marker. It was named so because of its interaction with phosphoryl choline and 
lipoteichoic acid found on pneumococcus. 
               CRP is the best known of the acute phase protein since it is regularly used 
as a marker of systemic inflammation in clinical settings
49
. They may increase from 
1 mcg/ml to 500mcg/ml in severe inflammation.
50 
                 
 
  
                 It is released in excess amount within 6 hours of an acute inflammatory 
stimulus. Doubling time in plasma occurs atleast every 8 hours. It attains the peak 
concentration after 50 hours. 
                The plasma concentration can fall almost as rapidly as 5-7hours plasma 
half life after appropriate treatment or removal of the inflammatory stimulus. 
CRP is a member of the pentraxin family of proteins. It also includes homologues of 
similar size proteins such as serum amyloid protein (SAP) or larger proteins such as 
long pentraxins (PTX3) . 
               C-reactive protein specifically binds to phosphocholine present on the cell 
membrane of microbes and it activates the classical complement pathway and inturn 
opsonizes the ligands for phagocytosis. It down regulates the polymorphs and also 
neutralizes the platelet activating factor. 
               Although in the clinical context elevation of CRP is suggestive of infection 
or inflammation, it may also occur with various other conditions like obesity, 
malignancy and renal dysfunction. Conversely, a lack of elevation of CRP is seen 
during flairs of systemic lupus erythematosus as well as in patients with hepatic 
failure. 
 
 
  
Conditions with elevated CRP: 
1.Bacterial infections such as pyelonephritis, meningitis and endocarditis. 
2.Inflammatory diseases such as Rheumatoid Arthritis , Psoriatic Arthritis, Reiters  
Disease, Crohns Disease , Ankylosing Spondylitis And Familial Mediterranean 
Fever . 
3.Malignancies such as lymphoma and sarcoma . 
4.Necrotic infection such as acute pancreatitis, myocardial infarction and tumor 
embolization . 
5. Other nonspecific conditions such as burns and fractures . 
 Levels of C-reactive protein in some conditions remained normal inspite of active 
inflammation which includes, 
          1. SLE 
          2. Dermatomyositis 
          3. Systemic sclerosis 
          4. Graft versus host disease 
          5. Leukaemia 
          6. Ulcerative colitis 
                            
 
            
 
          The reason for this selective failure of raise in CRP in the above said 
conditions is unknown. 
CRP and cardiovascular disease: 
          Atherosclerosis is the process underlying cardiovascular disease. It is partly 
responsible for the chronic low level inflammation of the vascular endothelium . 
Inflammation is obvious at the site of plaque rupture
51
. 
          Several studies like MRFIT
52 
and WHI study in postmenopausal women 
support the above fact. 
Apart from its use as an inflammatory marker it is also used in 
1. Assessing the response to treatment in conditions such as rheumatoid 
arthritis where there will be a dramatic fall in CRP level following 
treatment. 
2.To differentiate bacterial and viral infections (usually elevated in bacterial 
infection) 
3. To avoid confusion between a disease flare and super infection in 
conditions such as systemic lupus erythematosus.  
                CRP levels remains unaltered by antipyretic or any other thermoregulatory 
factors. So it can be used as an adjunct to use temperature chart in clinical practice. 
                    
 
              Recent works done in relation with cognitive assessment reveals that levels 
of CRP are high in those with impaired cognition.
53 
The exact etiology for this is 
unknown. Further work is warranted in this field. 
High sensitivity CRP: 
             Though both measure the same substance in blood, Ultra sensitive or high 
sensitivity CRP
54  
refers to the measurement of small changes in CRP concentrations 
which the standard test used for measuring CRP tend to miss. 
 Standard test for CRP measures only values more than 10 mg/L . Values less than 
10mg/L can be measured only by hs-CRP.
58 
It is synthesized from the  liver. 
              COPD is a chronic inflammatory disease of the lung, that is known  to have 
systemic features, among which is an increased risk of cardiovascular disease. 
Cardiovascular diseases  are the most potent killers particularly so in the advanced 
countries of the world. Cardiovascular disease is a leading cause of death in patients 
with COPD.
70
 
Pro-atherothrombotic mechanisms in COPD
6 
                Four factors seem to be pathogenetically important:  
1) Chronic systemic inflammation, 
2) Hypercoagulable state,  
3) Platelet activation and  
4) Oxidative stress 
  
 
 
Systemic inflammation: 
            In the context of the complex and multifactorial pathogenesis of 
atherothrombosis, low grade systemic inflammation is one of the crucial mechanism 
in plaque formation and rupture. Alveolar macrophages, bronchial epithelial cells 
and lymphocytes, which are implicated in bronchial and alveolar inflammation, 
produce interleukin (IL)-6 and IL-1β. 
             These cytokines, inducing local pro-inflammatory changes, “spill-over” into 
the systemic circulation and stimulate hepatocytes to synthesize inflammatory 
mediators. 
Hypercoagulable state: 
                 The increased procoagulant activity in COPD may primarily result from 
inflammation. Inflammation can trigger coagulation by promoting tissue-factor gene 
expression in endothelial cells. 
                Hypoxia also could  reduce endothelial thrombomodulin expression or 
activate factor X.  Coagulation, in turn, increases  inflammation and both are 
strongly implicated in the pathogenesis of atherothrombosis. 
 
Platelet activation: 
              Platelet stimulation may result from clotting activation with thrombin 
generation, that, in turn,  to enhance platelet thromboxane biosynthesis. 
Oxidative stress: 
              The development of COPD is associated with oxidative stress and reduced 
antioxidant properties. Hydrogen peroxide (H2O2) in exhaled breath condensate is a 
marker of oxidative stress in the lungs and have been found to be elevated in COPD 
patients irrespective of smoking status. 
               Oxidative stress can promote the peroxidation of polyunsaturated fatty 
acids. Pulmonary oxidative stress “spreads out” to the circulation and becomes a 
systemic alteration. 
                
                 COPD is now recognized as a systemic inflammatory disease that may 
adversely affect the arterial district, predisposing patients to an increased risk of 
atherosclerotic plaque formation and rupture. Systemic inflammation plays a 
leading role in this process, but other mechanisms, such as platelet activation, 
coagulation and oxidative stress, can promote atherosclerosis in COPD. 
                 Elevated serum lipoprotein(a) (Lp[a]) is an independent predictor of 
coronary artery disease (CAD) and myocardial infarction, intermittent claudication, 
cerebrovascular disease, and peripheral vascular disease.
72 
Lipoprotein(a):- 
                Lp(a) is composed of an LDL particle which, through its apolipoprotein 
B100 (apoB100) moiety, is covalently bonded to a glycoprotein molecule known as 
apolipoprotein(a) [apo(a)]. High   Lipoprotein[a]   serum   concentration   have   
been associated   with   atherosclerotic   disease   and   is considered   as   a   strong   
independent   risk   factor   for cardiovascular   disease  and cerebrovascular disease 
in COPD  patients. In neumours trials patients with Lp[a] levels above 30mg/dl had 
markedly increased risk of atherosclerotic disease
57,58
. 
Method  Of  Measurement : 
                                    IMMUNOTURBIDIMETRY 
. 
 
                           
                          MATERIALS AND METHODS 
                      The study was conducted at the Department of Biochemistry at Chennai 
medical college hospital and research centre during JANUARY 2014 – 
DECEMBER  2014. 
TOTAL NUMBER OF PATIENTS INCLUDED IN THE STUDY : 
                  Case -50  patients (both males & females). 
                  Control – 30 patients (both males & females). 
STUDY DESIGN: 
                   This is a case control study. 
INCLUSION CRITERIA: 
            COPD patients whose diseases were diagnosed by specialists and confirmed 
by  spirometry (as gold criteria). 
EXCLUSION CRITERIA: 
 1.Patients had a history of asthma, connective tissue disorders like [RA,SLE ], 
Inflammatory  disease [inflammatory  bowel  disease] and  malignancy. 
  2. Patients had acute or chronic renal failure, thyroid disorders, acute infection, 
stroke, and diabetic ketoacidosis. 
 
 
 
 
      
       ETHICAL CONSIDERATIONS: 
            Necessary approval to conduct the study at the Chennai medical college 
hospital and research centre was obtained from institutional ethical committee. 
Patients were given an explanation about the purpose of the study and informed 
written consent was obtained, confidentiality about their results was assured. Their 
participation was optional. 
COLLECTION OF SPECIMENS: 
             5ml venous blood sample was collected under fasting and aseptic 
precautions in clot activator coated polypropylene tubes. Blood was centrifuged at 
3500 rpm for 10 minutes and serum was separated. The specimens were freezed     
at -20°C for storage. 
ANALYSIS OF BLOOD SAMPLES: 
               The serum collected above was used for the estimation of the following 
parameters 
 
 
 
 
 
 
 ESTIMATED PARAMETERS: 
1) Serum High sensitivity C - Reactive protein by Immunoturbidimetry.    
2) Serum Lipoprotein[a] by Immunoturbidimetry.   
3) Serum Total Cholesterol by Enzymatic Cholesterol esterase method. 
4) Serum Triglycerides by Colorimetric Enzymatic Test using GPO. 
5) Serum High Density Lipoprotein Cholesterol by Direct enzymatic method.  
 
CALCULATED PARAMETERS: 
1. Body Mass Index (BMI):       Weight in Kg 
                                            (Height in meters)
2 
 
2. Very Low Density Lipoprotein cholesterol =  TGL/5 
3.  Low Density Lipoprotein cholesterol  = Total Cholesterol – ( LDL-c + VLDL-c ) 
 
 
 
 
 
ESTIMATION OF  SERUM HIGH SENSITIVITY                                                                 
C-REACTIVE PROTEIN 
Methodology: 
                  Latex enhanced Immunoturbidimetry.
 
Immunoturbidimetry: 
                 It is defined as the detection of light energy scattered towards a detector 
that is not in the direct path of transmitted light. Commonly available 
immunoturbidimeters are those which measure the scattered light at right angles to 
the incident light. It is the commonly used technique for protein assays such as 
Lipoprotein(a), C-reactive protein, rheumatoid factor, anti streptolysin O and 
immunoglobulins. 
Principle: 
            This CRP test is based upon the reactions between C-reactive  protein (CRP) 
and latex-covalently bound antibodies against human CRP. CRP values are 
determined turbidimetrically using fixed-time measurement with sample blank 
correction. 
                  The relationship between absorbance and concentration permits a 
multipoint calibration with a measuring range between 0 to 50 mg/L. The measuring 
temperature is 37°C. The assay can be performed on all instruments allowing 
turbidimetric measurements at 546 nm. 
 
 Reagents: 
A. Buffer – 30ml of  TRIS buffer(0.05), pH :7.2, containing polyethyleneglycol and 
0.09% sodium azide as preservative. 
B. Latex reagent – 5.1 ml of polystyrene particles (0.5%)  coated with goat antibodies 
anti-human-CRP serum  in a glycine buffer (0.1 M, pH :8.2), containing Nacl 
(0.15M) and bovine serum albumin (0.5%). 
Preservative: Sodium azide 0.075% 
Preparation of reagents: 
              Working Reagent is prepared with 1 part of Latex Reagent and 7 parts of 
Buffer Reagent. 
Procedure: 
       The sample and the working reagent  are  brought to room temperature prior to 
use. Latex reagent should be gently shaken before each use. 
 
 
 
 
 
 
 
 
 
Calibrator 1 6.25 mg/L 
Calibrator 2 12.5 mg/L 
Calibrator 3 25mg/L 
Calibrator 4 50 mg/L 
   CALIBRATOR  CURVE  OF  HIGH  SENSITIVITY                           
C- REACTIVE  PROTEIN 
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             3 test tubes are taken and labeled  them as blank (B), Calibrator (C), Test 
(T). 500µL of working reagent is added to 3 test tubes. 4 µL of distilled water  is 
added  to test tube labeled „B‟ and  4 µL of serum  is added  to test tube labeled „T‟ 
and 4 µL of Calibrator is added to test tube labeled „C‟. It is mixed and absorbance 
(A1) is read immediately at 550nm and the mixture is incubated for 4 minutes ,the 
absorbance (A2)  is read. 
 
 
 
 
 
 
 
Calculations: 
(A2 - A1 )sample      -   (A2 - A1 )blank       ×   calib.conc  = Sample concentration (mg/L)      
(A2 - A1 )calibrator          (A2 - A1 )blank 
 
Reference values: 
                        Serum HsCRP  < 6 - 8  mg/L. 
 
 
 Blank  calibrator    Test 
Working Reagent      500µL    500µL   500µL 
Calibrator         --     4 µL      -- 
Serum         --       --     4µL 
Distilled water       4 µL       --      -- 
                  
                       ESTIMATION  OF  SERUM  LIPOPROTEIN(a) 
Methodology: 
                         Latex enhanced Immunoturbidimetry. 
Principle: 
                   The Lp(a) test is based upon the reactions between Lp(a) in the sample 
and latex-covalently bound antibodies against human Lp(a). Lp(a) values are 
determined photometrically. 
Reagents: 
A. Buffer – 30ml of Glycine buffer , pH :8.0, containing protein stabilizers and 
0.09%  sodium azide as preservative. 
B. Latex reagent – 4ml of a suspension of latex microparticles covalently bound 
antibodies against human Lp(a) in a glycine buffer (0.1 M, pH :8.2), containing 
Nacl (0.15M) and bovine serum albumin (0.5%). Preservative : Sodium azide 
0.075% 
C. Calibrator – lyophilised for 1mL. Human – based reference fluid.       
Preservative: sodium azide, 0.075% . 
 
 
 
 
 Preparation of reagents: 
              Working Reagent is prepared with 1 part of Latex Reagent and 7 parts of 
Buffer Reagent. 
Procedure: 
       The sample and the working reagent  are  brought to room temperature prior to 
use. Latex reagent should be gently shaken before each use. 
 
 
 
 
 
 
                    3 test tubes are taken and labeled  them as blank (B), Calibrator (C), 
Test (T). 500µL of working reagent is added to 3 test tubes. 4 µL of distilled water  
is added  to test tube labeled „B‟, 4 µL of sample  is added  to test tube labeled „T‟ 
and 4 µL of Calibrator is added to test tube labeled „C‟. It is mixed and absorbance 
(A1) is read immediately at 600nm and the mixture is incubated for 4 minutes ,the 
absorbance (A2)  is read.  
 
 
Calibrator 1 59 mg/L 
Calibrator 2 119 mg/L 
Calibrator 3 238 mg/L 
Calibrator 4 475 mg/L 
                       CALIBRATOR  CURVE  OF  LIPOPROTEIN(a) 
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 Calculations: 
(A2-A1 )sample    -     (A2 - A1 )blank      ×   calib.conc  =  Sample concentration(mg/L)      
(A2 - A1 )calibrator       (A2 - A1 )blank 
 
Reference values: 
                   Serum Lipoprotein(a)   < 300 mg/L. 
 
 
 
 
 
 
                                  
    Blank  Calibrator    Test 
Working Reagent    500µL     500µL   500µL 
        Calibrator        --      4 µL       -- 
Sample        --        --     4µL 
    Distilled water      4 µL        --       -- 
                                    LIPID PROFILE  
            ESTIMATION  OF  SERUM  TOTAL  CHOLESTEROL      
Methodology: 
                         Cholesterol Oxidase / Peroxidase method
 
Principle of the method: 
               Cholesterol esters are hydrolyzed to produce cholesterol. Then, free 
cholesterol takes part in two coupled reactions that permit to measure cholesterol 
photometrically. 
The reaction sequence is as follows: 
Cholesterol ester + H2O     Chol.esterase         Cholesterol + Fatty acid 
 
                 Chol.Oxidase 
Cholesterol + ½ O2 + H2O               Cholestenone +  H2O2 
                Peroxidase 
2H2O2 + 4- Aminoantipyrine + Phenol               Quinoneimine + 4H2O 
 
Reagents:  
              Pipes                                  35mmol / L 
              Sodium cholate                  o.5mmol / L 
              Phenol                                28mmol/L 
               
 
             
              Cholesterol esterase           >0.2 U/mL 
              Cholesterol oxidase            >0.1U/mL 
              Peroxidase                           >0.8U/mL 
              4-Aminoantipyrine              0.5mmol/L 
              pH                                        7.0 
Standard : 
                        Cholesterol 200mg/dl 
Storage:      2ºC-8ºC 
Preparation of working solution: 
             Both the working reagent and the standard are supplied ready to use. 
Procedure: 
              The sample and the working reagent are brought to room temperature prior 
to use. Working reagent should be gently shaken before each use. 
 
 
 
 
 
 
 
 
 Blank Standard Test 
Working Reagent 1Ml 1mL 1mL 
Distilled water 10µL -- -- 
Standard -- 10µL -- 
Sample -- -- 10µL 
  
            3 test tubes are taken and labeled  them as blank (B), Standard (S), Test (T). 
1 ml of working reagent is added to 3 test tubes. 10µL of distilled water  is added  to 
test tube labeled „B‟, 10µL of sample  is added  to test tube labeled „T‟ and 10µL of 
standard is added to test tube labeled „S‟. It is mixed and incubate the tubes for 10 
minutes at room temperature. Read the absorbance at 500±10nm. 
 
        Calculations: 
Sample absorbance    ×  200  = Sample concentration(mg/dl)      
Standard absorbance 
 
Reference values: 
Serum Total Cholesterol: 
            Desirable               : up to 200 mg/dl 
            Borderline High     : 200 - 239 mg/dl 
            High                      : > 240 mg/dl. 
 
 
 
 
 
 
 ESTIMATION  OF  SERUM  TRIGLYCERIDES 
Methodology: 
                       Glycerol-3-phosphate oxidase (GPO)
 
Principle of the method: 
           Determination of triglycerides after enzymatic splitting with lipoprotein 
lipase. Indicator is quinoneimine which is generated from 4-aminoantipyrine and   
4- chlorophenol by hydrogen peroxide under the catalytic action of peroxidase. 
The reaction sequence is as follows: 
        LPL 
Triglycerides                        Glycerol + Fatty acid     
 
                                GK 
Glycerol + ATP                    Glycerol-3-phosphate + ADP 
                    GPO  
Glycerol-3-phosphate + O2                                  Dihydroxyaceton phosphate + H2O2  
                        POD       
         2H2O2 + Aminoantipyrine + 4-Chlorophenol                 Quinoeimine + HCl +4 H2O  
Reagents:  
              4-chlorophenol                                 4mmol / L 
              ATP                                                 2mmol / L 
              Mg
2+
                                                15mmol/L 
               
 
 
          
          Glycerolkinase(GK)                           ≥0.4 kU/L 
          Lipoprotein lipase(LPL)                     ≥ 2 kU/L 
          Peroxidase(POD)    ≥ 2 kU/L 
          4-Aminoantipyrine                      0.5mmol/L 
          Glycerol-3-phosphateoxidase(GPO)  ≥0.5 kU /L 
          Good‟s buffer pH        7.2               50 mmol / L 
Standard : 
                         Triglycerides  200mg/dl 
Storage:      2ºC-8ºC 
Preparation of working solution: 
                   Both the working reagent and the standard are supplied ready to use. 
Procedure: 
       The sample and the working reagent  are  brought to room temperature prior to 
use. Working reagent should be gently shaken before each use. 
 
 
 
 
 
 
 
 Blank Standard Test 
Working Reagent 1ml 1ml 1ml 
Distilled water 10µL -- -- 
Standard -- 10µL -- 
Sample -- -- 10µL 
              
 
                3 test tubes are taken  and labeled  them as blank (B), Standard (S), Test 
(T). 1 ml of working reagent is added to 3 test tubes. 10µL of distilled water  is 
added  to test tube labeled „B‟, 10µL of sample  is added  to test tube labeled „T‟ 
and 10µL of standard is added to test tube labeled „S‟. It is mixed and incubate the 
tubes for 10 minutes at room temperature. Read the absorbance at 546nm. 
Calculations: 
                Sample absorbance     ×   200 =  Sample concentration (mg/dl)      
               Standard absorbance 
                  
                 To correct for free glycerol, subtract 10mg/dl from the triglycerides value 
calculated above. 
Reference values: 
Serum Triglycerides: 
                          Desirable                  : < 200 mg/dl 
                          Borderline High       : 200 - 400 mg/dl 
                          High                          : > 400 mg/dl 
 
 
 
 
 ESTIMATION  OF  SERUM 
HIGH  DENSITY  LIPOPROTEIN  CHOLESTEROL 
Methodology: 
                           Direct enzymatic method.
 
Principle: 
                   Antibodies against human lipoproteins are used to form antigen-antibody 
complexes with LDL, VLDL and chylomicrons in a way that only HDL-cholesterol 
is selectively determined by an enzymatic cholesterol measurement. 
The reaction sequence is as follows: 
                                      Anti-human  
     β – lipoprotein antibodies 
LDL,VLDL,                                                      Antigen – antibody complexes +HDL 
Chylomicrons 
                    CHE &CHO 
HDL–Cholesterol + H2O +O2                                      Cholest-4-en-3-one + Fatty acid +  
          H2O2 
                   POD 
H2O2  + F- DAOS + 4- Aminoantipyrine                     Blue Complex +H2O 
 
 
 
 
 
 Reagents: 
Reagent 1: 
Ascorbate oxidase                                         2250 U/ L 
Anti-human β - lipoprotein 
Antibody(sheep) 
 Peroxidase                                                    2000 U/L 
 4-Aminoantipyrine                                       0.75mmol/L 
Good‟s buffer pH        7.0                             25 mmol / L 
 Reagent 2: 
 Good‟s buffer pH        7.0                           30 mmol / L 
 Cholesterol esterase(CHE)                          4000 U/L 
  Cholesterol  oxidase(CHO)                        20000U/L 
   N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-     0.8mmol/L 
   3,5- dimethoxy-4-fluoroaniline, 
   Sodium salt           (F-DAOS) 
Calibrator : 
                                         HDL-Cholesterol   50.6 mg/dl 
      Storage:      2ºC-8ºC 
 
 
 Preparation of working solution: 
Both the working reagent and the standard are supplied ready to use. 
 
 
 
 
 
 
 
Procedure: 
                    The sample and the working reagent  are  brought to room temperature 
prior to use. Working reagent should be gently shaken before each use. 
                    3 test tubes are taken  and labeled  them as blank (B), Calibrator (C), 
Test (T). 240µL of working reagent 1 is added to 3 test tubes. 2.4µL of distilled 
water  is added  to test tube labeled „B‟, 2.4µL of sample  is added  to test tube 
labeled „T‟ and 2.4 µL of calibrator is added to test tube labeled „C‟. It is mixed and  
 
 
 
 
 Blank Calibrator Test 
Calibrator -- 2.4 µL -- 
Sample -- -- 2.4 µL 
Reagent 1 240 µL 240µL 240 µL 
Mix, incubate 5min at 37°C,read absorbance A1Then add: 
Reagent 2 60 µL 60µL 60µL 
Mix, incubate 5 min at 37°C,read absorbance A2. 
  
incubate the tubes for 5 minutes at room temperature. Read the absorbance A1 at 
600/700nm,  then 60µL of working reagent 2 is added to 3 test tubes. It is mixed 
and incubate the tubes for 5 minutes at room temperature. Read the absorbance A2. 
              
                    ΔA = (A2- A1) sample or calibrator. 
Calculations: 
ΔASample        ×  conc.Calib  = Sample concentration(mg/dl)      
ΔA Calibrator 
 
Reference values: 
                               Serum HDL-C    ≥ 35mg/dl. 
 
CALCULATED PARAMETERS: 
1. VERY LOW DENSITY LIPOPROTEIN-C  =  Triglycerides 
                                                                                          5 
2.  LOW DENSITY LIPOPROTEIN-C = Total Cholesterol – HDL -  Triglycerides 
                                                                                                                          5 
 
 
 
 
 RESULTS AND STATISTICAL ANALYSIS 
Table 1 Age distribution of the study population (n=80) 
Age group 
Cases  
N (%) 
Controls  
N (%) 
Total 
N (%) 
21- 30 years 0 (0) 4 (13.3) 4 (5) 
31 - 40 years 6 (12) 8 (26.7) 14 (17.5) 
41 – 50 years 2 (4) 9 (30) 11 (13.8.7) 
51 – 60 years 16 (32) 5 (16.7) 21 (26.2) 
61 – 70 years 20 (40) 4 (13.3) 24 (30) 
71 – 80 years 6 (12) 0 (0) 6 (7.5) 
Total 50 (100) 30 (100) 80 (100) 
 
Mean age: 54.2 years 
Standard deviation: 3.81 years 
 Minimum: 27 years 
Maximum: 79 years 
 
 Fig 1: Bar diagram showing Age distribution of the study population (n=80) 
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 Table 2 Comparison of age among cases and controls (n=80) 
Student “t” test 
 
Group Mean Age 
Std. 
Deviation 
Mean 
difference 
p value 
95% 
confidence 
interval 
Cases 59.86 11.22 
15.09 0.001 9.767 – 20.41 
Controls 44.77 12.16 
 
 
Comments: 
 Subjects in the Cases group had a mean age of around 60 years and subjects in 
control group had a mean age of 45 years and this mean difference was statistically 
significant.  
 
 
 Table 3 Gender distribution of the study population (n=80) 
 
Gender 
Cases  
N (%) 
Controls  
N (%) 
Total 
N (%) 
Male 32 (64) 17 (56.7) 49 (61.3) 
Female 18 (36) 13 (43.3) 31 (38.8) 
Total 50 (100) 30 (100) 80 (100) 
 
Chi square value: 0.425   p value: 0.515 
 
Comments:  
                   Males and females were equally distributed in both cases and controls. 
 
 
 
 
  
Fig 2: Bar diagram showing sex distribution of the study population (n=80) 
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Table 4 Distribution of the cases according to spirometry staging (n=50) 
 
Spirometry stage Frequency (N) 
Percentage 
(%) 
Stage I 13 26 % 
Stage II 14 28 % 
Stage III 13 26 % 
Stage IV 10 20 % 
Total 50 100 % 
 
Comments:  
                     Cases were distributed almost equally in all 4 stages of spirometry. 
 
 
 
  
Fig 3: Bar chart showing distribution of cases among stages of spirometry 
(n=50) 
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 Table 5 Distribution of the cases according to BMI status (n=50)  
BMI classification* Frequency (N) 
Percentage 
(%) 
Undernourished (<18.5) 1 2 % 
Normal 
(18.5 to 22.9) 
27 54 % 
Overweight 
(23 to 24.9) 
11 22 % 
Obese 
(>25 ) 
11 22 % 
Total 50 100 % 
 
*According to South Asian classification of obesity 
Mean BMI: 23.28 kg/m
2
 
Standard deviation: 2.64 kg/m
2
 
 Minimum BMI: 14 kg/m
2
 
Maximum BMI: 34 kg/m
2
 
Comments:  
         About 44% of cases were either overweight or obese while 54% of cases had normal BMI. 
 
  
Fig 4:Pie chart showing distribution of cases according to BMI status (n=50) 
 
 
 
 
 
 
1
27
11
11
BMI Groups
Undernourished 
(<18.5)
Normal
Overweight
Obese
 Table 5 Distribution of the cases according to disease duration (n=50) 
 
Disease duration Frequency (N) 
Percentage 
(%) 
< 10 years 10 20 % 
11 to 20 years 32 64 % 
>20 years 8 16 % 
Total 50 100 % 
 
Mean disease duration: 15.08 years 
Standard deviation: 5.2 years 
 Minimum: 6 years 
Maximum: 28 years 
Comments:  
         About 80% of cases had COPD for more than 10 years duration and 16% of cases 
had the disease for more than 20 years. 
 
Fig 5:Doughnut diagram showing distribution of cases according to duration 
of COPD (n=50) 
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 Table 7 Distribution of the cases according to smoking status (n=50) 
 
Smoking status Frequency (N) 
Percentage 
(%) 
Non-smoker 18 36 % 
Ever smoker 32 64 % 
Total 50 100 % 
 
Among Smokers: 
                                                Mean pack years: 25.71 years 
Standard deviation: 7.53 years 
 Minimum: 12 years 
Maximum: 39.5 years 
Comments: 
              All the smokers among the cases were addicted for more than 10 years and the 
mean pack years of smoking (25) depicts the magnitude of the smoking. 
 
 
 Fig 6: Pie diagram showing distribution of cases according to smoking status 
(n=50) 
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 Table 8 Comparison of HsCRP levels among cases and controls (n=80) 
Student “t” test 
 
Group 
Mean 
HsCRP 
level 
(mg/L) 
Std. 
Deviation 
Mean 
difference 
p value 
95% 
confidence 
interval 
Cases 12.66 13.92 
9.16 0.001 4.066 – 14.254 
Controls 3.50 1.57 
 
Comments: 
 Subjects in the Cases group had a mean HsCRP level of 12.66 mg/L which is 
roughly 9 units higher than the mean HsCRP level of control group (3.5 mg/L) and this 
mean difference was statistically significant.  
 
 
 
  
Fig 7: Bar diagram showing serum HsCRPlevel distribution of the study 
population (n=80)  
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 Table 9 Distribution of the cases according to spirometry staging and HsCRP 
levels (n=50)  
Spirometry 
staging 
N 
Mean 
HsCRP 
levels 
(mg/L) 
Std. 
Deviation 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
Stage I 13 2.00 .913 1.45 2.55 
Stage II 14 4.36 2.499 2.91 5.80 
Stage III 13 14.23 8.927 8.84 19.63 
Stage IV 10 36.10 7.370 30.83 41.37 
Total 50 12.66 13.928 8.70 16.62 
 
         ANOVA test was applied to test the difference in mean HsCRP levels 
between the groups followed by Bonferroni post-Hoc test for inter-group comparisons. 
                                                     ANOVA test 
 
 
 
 
p value <0.001 
F statistic 79.528 
Degree of freedom 3 
Bonferroni Post-Hoc test 
Dependent Variable (HsCRP 
levels) 
Mean 
Difference  
P value 
Stage 1 Vs Stage 2 -2.35 1.00 
Stage 1 Vs Stage 3 -12.23 <0.001* 
Stage 1 Vs Stage 4 -34.10 <0.001* 
Stage 2 Vs Stage 3 -9.87 <0.001* 
Stage 2 Vs Stage 4 -31.74 <0.001* 
Stage 3 Vs Stage 4 -21.86 <0.001* 
 
*significant at <0.05 level 
Comments: 
1) ANOVA test showed that there is a statistically significant difference in the mean 
HsCRP levels between the 4 groups. 
2) Bonferroni test showed that the difference in mean HsCRP levels between Stage 1 Vs 
Stage 3, Stage 1 Vs Stage 4, Stage 2 Vs Stage 4 and Stage 3 Vs Stage 4 is statistically 
significant (all p values <0.05) and that the severity of disease increases with increase in 
mean HsCRP levels and vice versa. 
Table 10 Distribution of the cases according to spirometry staging and BMI 
levels (n=50)  
Spirometry 
staging 
N 
Mean 
BMI 
Std. 
Deviation 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
Stage I 13 20.154 1.4345 19.287 21.021 
Stage II 14 21.571 3.8871 19.327 23.816 
Stage III 13 24.446 3.9428 22.064 26.829 
Stage IV 10 28.260 5.2502 24.504 32.016 
Total 50 23.288 4.7150 21.948 24.628 
 
               ANOVA test was applied to test the difference in mean BMI levels between the 
groups followed by Bonferroni post-Hoc test for inter-group comparisons. 
ANOVA test 
p value <0.001 
F statistic 10.139 
Degree of freedom 3 
 
 
 
Bonferroni Post-Hoc test 
Dependent Variable (BMI 
levels) 
Mean 
Difference  
P value 
Stage 1 Vs Stage 2 -1.41 1.00 
Stage 1 Vs Stage 3 -4.29 0.034* 
Stage 1 Vs Stage 4 -8.10 <0.001* 
Stage 2 Vs Stage 3 -2.87 0.324 
Stage 2 Vs Stage 4 -6.68 0.001* 
Stage 3 Vs Stage 4 -3.81 0.123 
 
*significant at <0.05 level 
Comments: 
1) ANOVA test showed that there is a statistically significant difference in the mean BMI 
levels between three groups. 
2) Bonferroni test showed that the difference in mean BMI levels between Stage 1 Vs 
Stage 3, Stage 1 Vs Stage 4 and Stage 2 Vs Stage 4 is statistically significant (all p values 
<0.05) and that the severity of disease increases with increase mean BMI levels and vice 
versa. 
 
Table 11 Distribution of the cases according to spirometry staging and 
duration of COPD (n=50) 
 
 
 
 
 
 
 
 
 
           
ANOVA test was applied to test the difference in mean duration of COPD in years 
between the groups. 
                                                     ANOVA test 
p value 0.484 
F statistic 0.831 
Degree of freedom 3 
Comments:  
             There was no statistically significant association between duration of COPD and 
spirometry staging. 
Spirometry 
staging 
N 
Mean 
duration 
of COPD 
in years 
Std. 
Deviation 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
Stage I 13 14.54 5.840 11.01 18.07 
Stage II 14 14.29 3.970 11.99 16.58 
Stage III 13 14.69 5.170 11.57 17.82 
Stage IV 10 17.40 6.041 13.08 21.72 
Total 50 15.08 5.213 13.60 16.56 
 Table 12 Distribution of the cases according to spirometry staging and 
smoking as categorical variable (n=50) 
 
Chi-square value: 4.861  p Value: 0.182 
Comments: 
                   There was no statistically significant association between smoking status and 
spirometry staging of COPD when smoking is taken as a binomial categorical variable. 
 
Spirometry stage 
Smoker 
N (%) 
Non-smokers 
N (%) 
Total 
N (%) 
Stage 1 9 (28.1) 4 (22.2) 13 (26) 
Stage 2 7 (21.9) 7 (38.9) 14 (28) 
Stage 3 7 (21.9) 6 (33.3) 13 (26) 
Stage 4 9 (28.1) 1 (5.6) 10 (20) 
Total 32 (100) 18 (100) 50 (100) 
 Table 13 Distribution of the cases according to spirometry staging and 
smoking as continuous variable (in pack-years) (n=50) 
 
 
 
              
ANOVA test was applied to test the difference in mean  smoking pack-years between the 
groups followed by Bonferroni post-Hoc test for inter-group comparisons. 
ANOVA test 
 
 
 
 
Spirometry 
staging 
N 
Mean 
smoking 
pack-
years 
Std. 
Deviation 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
Stage I 13 11.81 9.2478 6.219 17.396 
Stage II 14 12.11 12.6691 4.792 19.422 
Stage III 13 15.42 15.1215 6.285 24.561 
Stage IV 10 29.95 11.2779 21.882 38.018 
Total 50 16.46 13.8372 12.528 20.392 
p value 0.003 
F statistic 5.213 
Degree of freedom 3 
 Bonferroni Post-Hoc test 
Dependent Variable (Smoking 
pack-years) 
Mean 
Difference  
P value 
Stage 1 Vs Stage 2 -0.299 1.00 
Stage 1 Vs Stage 3 -3.61 1.00 
Stage 1 Vs Stage 4 -18.14 0.006* 
Stage 2 Vs Stage 3 -3.31 1.00 
Stage 2 Vs Stage 4 -17.84 0.006* 
Stage 3 Vs Stage 4 -14.52 0.045* 
 
*significant at <0.05 level 
Comments: 
1) ANOVA test showed that there is a statistically significant difference in the mean 
smoking pack-years between three groups. 
2) Bonferroni test showed that the difference in mean BMI levels between Stage 1 Vs 
Stage 4, Stage 2 Vs Stage 4 and Stage 3 Vs Stage 4 is statistically significant (all p values 
<0.05) and that the severity of disease increases with increase mean smoking pack-years  
but significantly increased in stage 4 and vice versa. 
  
Fig 8 : Showing comparison of various parameters according to stages of 
spirometry among cases (n=50) 
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 Table 14 Distribution of the cases according to Duration of COPD and BMI 
levels (n=50) 
BMI 
Duration of COPD 
Total 
<10 years 11 to 20 years >20 years 
<18.5 0 (0%) 1 (2%) 0 (0%) 1 (2%) 
18.5 - 22.9 5 (10%) 18 (36%) 4 (8%) 27 (54%) 
23  - 24.9 2 (4%) 6 (12%) 3 (6%) 11 (22%) 
>25 3 (6%) 7 (14%) 1 (2%) 11 (22%) 
Total 10 (20%) 32 (64%) 8 (16%) 50 (100%) 
 
Chi square value: 2.311   p value: 0.889 
Comments:  
             There was no statistically significant association between BMI levels and duration 
of  COPD.  
 
 
 
 Table 15 Comparison of smoking status and duration of COPD among cases 
(n=50) 
Student “t” test 
 
Comments: 
 Smokers had a mean duration of COPD of around 16 years while cases not 
exposed to smoking had a mean duration of 13 years and this mean difference was 
statistically significant. Hence, the disease either sets early or persists longer in smokers. 
 
 
 
Group (N) 
Mean 
duration 
of COPD 
Std. 
Deviation 
Mean 
difference 
p value 
95% 
confidence 
interval 
Smokers (32) 16.25 5.22 
3.25 0.033* 0.276 – 6.224 
Non-smokers (18) 13 4.62 
 Table 16 Comparison of  Lipoprotein(a)  levels among cases and controls 
(n=80) 
Student “t” test 
 
Group 
Mean LP(a) 
level 
(mg/L) 
Std. 
Deviation 
Mean 
difference 
p value 
95% 
confidence 
interval 
Cases 211.68 143.00 
68.447 0.002 25.69  - 111.19 
Controls 143.23 37.84 
 
Comments: 
 Subjects in the Cases group had a mean LP(a) level of 211 mg/L which is roughly 
68 units higher than the mean LP(a) level of control group (143 mg/L) and this mean 
difference was statistically significant.  
 
 
  
Fig 9: Bar diagram showing serum Lipoprotein(a)  level distribution of the 
study population (n=80)  
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Table 17 Distribution of the cases according to spirometry staging and 
Lipoprotein (a) levels (n=50)  
Spirometry 
staging 
N 
Mean 
Lp(a) 
levels 
(mg/L) 
Std. 
Deviation 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
Stage I 13 220.46 115.784 150.49 290.43 
Stage II 14 212.29 142.973 129.74 294.84 
Stage III 13 183.38 199.074 63.09 303.68 
Stage IV 10 236.20 95.705 167.74 304.66 
Total 50 211.68 143.003 171.04 252.32 
 
ANOVA test was applied to test the difference in mean Lp(a)  levels 
between the groups followed by Bonferroni post-Hoc test for inter-group comparisons. 
ANOVA test 
p value 0.846 
F statistic 0.271 
Degree of freedom 3 
Comments: 
                ANOVA test showed that there is no statistically significant association 
between mean Lipoprotein(a) levels and the spirometry staging. 
 
  
Fig 10 : Showing comparison of mean serum lipoprotein (a) levels according 
to stages of spirometry among cases (n=50)  
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Table 18 Comparison of lipid parameters among cases and controls (n=80) 
Student “t” test 
 
Comments: 
            Cases had high levels of all the lipid parameters than controls and this 
difference in the mean levels of the above mentioned parameters were also 
statistically significant except for LDL cholesterol levels. 
Lipid parameters 
Cases 
(n=50) 
Controls 
(n=30) 
Mean 
difference 
(Cases - 
Controls) 
Student t test 
p value 
Total 
Cholesterol 
(mg/dl) 
Mean 
levels 
194.30 170.43 
23.867 0.001 
Standard 
deviation 
42.75 19.63 
Triglycerides 
(mg/dl) 
Mean 
levels 
127.88 97.17 
30.713 <0.001 
Standard 
deviation 
44.39 14.83 
HDL 
cholesterol 
(mg/dl) 
Mean 
levels 
47.88 37.87 
10.013 <0.001 
Standard 
deviation 
12.50 5.99 
LDL 
cholesterol 
(mg/dl) 
Mean 
levels 
120.88 113.13 
7.754 0.177 
Standard 
deviation 
33.53 17.27 
VLDL 
cholesterol 
(mg/dl) 
Mean 
levels 
25.57 19.43 
6.138 <0.001 
Standard 
deviation 
8.87 2.96 
 Fig 11: Clustered Bar chart comparing the mean serum levels of various 
parameters among cases and controls (N=80) 
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 Table 19: Correlation matrix between BMI , serum markers and                                           
Lipid parameters (n=50) 
 BMI Hs-CRP 
mg/L 
Lp(a) 
mg/L 
Total 
Cholester
ol 
mg/dl 
Triglyceri
des 
mg/dl 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-
C 
mg/dl 
BMI 1 0.640** -0.40 -0.191 -0.224 -0.311* -0.068 -0.224 
 
*p value<0.05 
Comments : 
1) There was a statistically significant positive linear correlation between BMI and 
serum Hs-CRP levels. i.e the increase in BMI also had a corresponding increase in 
serum Hs-CRP levels in the same direction. 
2) There was a statistically significant negative linear correlation between BMI and 
serum HDL  levels. i.e the increase in BMI also had a corresponding decrease in 
serum HDL  levels in the opposite direction. 
 
 
 
Table 20: Correlation matrix between disease duration, serum markers and 
Lipid parameters (n=50) 
 
*p value<0.05 
Comments: 
            There was no statistically significant correlation between disease duration 
and Hs-CRP, Lp(a) and Lipid profile. 
 
 
 
 
 
 
 
 
 Disease 
duration 
Hs-CRP 
mg/L 
Lp(a) 
mg/L 
Total 
Cholesterol 
mg/dl 
Triglycerides 
mg/dl 
HDL-C 
mg/dl 
LDL-C 
mg/dl 
VLDL-C 
mg/dl 
Disease 
duration 
1 0.099 0.098 0.073 0.013 0.0111 0.047 0.013 
  
Table 21 Multivariate Logistic regression model for COPD with 
predictors (n=80) 
 
Independent variable 
Dependent variable (COPD) 
p value 
Adjusted  
Odds ratio 
(AOR) 
95% confidence 
interval 
 
Age in years 
 
 
1.144 
 
 
1.067 – 1.226 
 
<0.001* 
Sex 
 Female 
 
Male 
 
 
2.811 
 
1 
 
 
0.796 – 18.23 
 
- 
 
0.094 
 
Serum HsCRP levels 
 
1.259 1.03 – 1.52 0.019 
 
Serum Lp (a) levels 
 
1.007 0.99 – 1.01 0.093 
 
Nagelkerke’s pseudo R square-62.3% 
 
 
 
 
 Comments: 
1. For every unit increase in age, the risk of COPD increased by 14% even 
after adjusting for other variables in the model and this odds ratio was 
statistically significant. 
2. For every unit increase in Serum HsCRP levels, the risk of COPD increased 
by 25% after adjusting for other variables in the model and this odds ratio 
was statistically significant. 
3. For every unit increase in Serum Lp(a) levels, the risk of COPD increased 
by 7% after adjusting for other variables in the model and females had a 
relatively higher risk of being in cases group with COPD than controls but 
these odds ratios were not statistically significant 
4. About 62.5% of variability in the occurrence of COPD can be explained by 
these 4 variables included in the model as given by Nagelkerke‟s pseudo R 
square. 
 
 
 
 
 
 
 Table 22: Correlation matrix between smoking, serum markers and lipid 
parameters (n=50) 
 
SMOKI
NG 
HsCRP 
(mg/L) 
LP(a) 
(mg/L) 
TOTAL 
CHOLE
STR0L 
(mg/dl) 
TRIGL
YCERI
DES 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg/dl) 
VLDL-
C 
(mg/dl) 
SMOKI
NG 
1 
       
HsCRP 
(mg/L) 
0.405
*
 1 
      
LP(a) 
(mg/L) 
0.110 0.045 1 
     
TOTAL 
CHOLE
STR0L 
(mg/dl) 
0.309 -0.257 0.347
*
 1 
    
TRIGL
YCERI
DES 
(mg/dl) 
-0.053 -0.118 0.127 0.316
*
 1 
   
HDL-C 
(mg/dl) 
-0.286
*
 -0.376
*
 0.105 0.661
*
 0.041 1 
  
LDL-C 
(mg/dl) 
-0.275 -0.156 0.368
*
 0.945
*
 0.125 0.459 1 
 
VLDL-
C 
(mg/dl) 
-0.052 -0.118 0.128 0.316
*
 0.31
*
 0.041 0.125 1 
 
*p value<0.05 
 
Comments: 
1) There was a statistically significant positive linear correlation between smoking 
and serum HsCRPlevels.i.e. the increase in pack years of smoking also had a 
corresponding increase in serum HsCRP levels in the same direction. 
2) There was a statistically significant negative linear correlation between smoking 
and serum HDL levels.i.e. the increase in pack years of smoking also had a 
corresponding decrease in serum HDL levels in the opposite direction. 
3) There was a statistically significant negative linear correlation between serum 
HsCRP levels and serum HDL levels .i.e. the increase in serum HsCRP levels 
also had a corresponding decrease in serum HDL levels in the opposite direction. 
4) There was a statistically significant positive linear correlation between serum 
lipoprotein (a) levels and serum total cholesterol , LDL cholesterol levels.i.e. the 
increase in serum lipoprotein (a) levels also had a corresponding increase serum 
total cholesterol , LDL cholesterol levels in the same direction. 
5) There was a statistically significant positive linear correlation between serum 
total cholesterol and all other lipid parameters as expected. 
6) There was a statistically significant positive linear correlation between serum 
triglyceride levels and serum VLDL cholesterol levels.i.e. the increase in serum 
triglyceride levels also had a corresponding increase in serum VLDL cholesterol 
levels in the same direction. 
                                         
                                                
                                              DISCUSSION 
             Chronic obstructive pulmonary disease is a major public health concern and is a 
leading cause of morbidity and mortality. The reliance upon expert opinion to develop the 
various worldwide COPD guidelines and the variation in the guidelines also likely reflect 
the fact that COPD is a heterogenous disease. The biomarkers to determine the severity 
of  COPD are necessary in the control of disease prognosis. 
 
           High Sensitivity C-Reactive Protein is one of the recently identified valid 
biomarker of low-grade systemic inflammation.
59
 
           In the present study, the mean Hs-CRP level in the case group was (12.66±13.92) 
significantly higher than in the control group (3.50±1.57)  with p value 0.001. These 
results were supported by studies of  Lisatileman , Lena ginder et al.,
60
 and  Sanjamarevic 
et al.,
61
both were proposed that Hs-CRP levels are significantly elevated in COPD 
patients than the control group. 
                In the present study, there was a significant increase in Hs-CRP in stage III  and 
stage IV COPD compared to stage I or stage II. The severity of disease increases with 
increase in mean Hs-CRP levels. These results were supported by studies of Tahia H 
saleem ,Manal A M Mandour et al.,
59
 and SAalavi et al.,
62
 both were proposed that      
Hs-CRP level was significantly correlated to stage of disease (as gold criteria). 
                
 
               In the present study, there was a significant increase in Hs-CRP level in 
smokers with COPD  than in non smokers with COPD and also the number of pack-years 
was positively correlated with Hs-CRP levels. These results were supported by studies of 
SAalavi et al.,
62
and Yannick M.T.A. et al.,
63
and Reshu Agarwal et al.,
64
were proposed 
that Hs-CRP level was significantly higher in smokers as compared to non smokers. 
               In the present study, there was a significant  increase in  BMI level also had a 
corresponding increase in serum Hs-CRP levels. These results were supported by studies 
of SAalavi et al.,
62 
Breyer MK et al.,
65 
and  PO Bridevaux et al.,
66 
were proposed that   
Hs-CRP level was significantly higher in obese COPD patients as compared to nonobese 
patients. 
               In the present study, there was a no correlation between the disease duration and 
Hs-CRP levels. These results were supported by study of Daianastolz et al.,
67
  who 
concluded the same in a group of 100 patients for a follow up period of  longer time >1yr. 
              In the present study, there was a significant negative correlation between serum 
Hs-CRP levels and serum HDL levels. The increase in serum Hs-CRP levels also had a 
corresponding decrease in serum HDL levels. 
               
  
              In the present study, there was a significant increase in severity of the disease  
also had a corresponding increase in mean BMI levels. 
              In the present study,  there was a significant increase in severity of the disease  
also had a corresponding increase in mean smoking pack-years and also significantly 
increased in stage IV. 
              In the present study,  there was a significant increase in age ,the risk of COPD 
also increased. 
              In the present study,  there was no significant association between duration of 
COPD and spirometry staging. 
               In the present study,  there was no significant association between BMI levels 
and duration of COPD. 
              COPD is a chronic inflammatory disease of the lung, that is known  to have 
systemic features, among which is an increased risk of cardiovascular disease. 
Cardiovascular diseases  are the most potent killers particularly so in the advanced 
countries of the world. Cardiovascular disease is a leading cause of death in patients with 
COPD.
70
 
             
  
             Lipoprotein (a) has emerged as a powerful genetic risk factor for coronary artery 
disease.
66
 
             In the present study, there was a significant increase in the mean Lipoprotein(a)  
level in the case group was (211.68±143.00) which was significantly higher than in the 
control group (143.23±37.84)  with p value 0.002.  
              In the present study, there was a significant positive correlation between serum 
lipoprotein(a) levels and serum total cholesterol , LDL cholesterol levels. The increase in 
serum lipoprotein(a) levels also had a corresponding increase serum total cholesterol and  
LDL cholesterol levels. 
              In the present study, there was no significant association between mean 
Lipoprotein(a) levels and the spirometry staging, BMI, smoking, disease duration. 
            Lipid parameter abnormalities are a highly important. Its alteration in lipid 
metabolism increases cardiovascular risk, and so the mortality and morbidity
71
. 
            In the present study, the mean levels of the all lipid parameters of case group had 
high level than the control group .P values of all lipid parameters were significant except 
LDL cholesterol level.
 
             
              In the present study, there was a significant negative correlation between 
smoking and serum HDL levels. The increase in pack years of  smoking also had a 
corresponding decrease in serum HDL levels. 
            In the present study, there was a significant negative correlation between BMI 
levels and serum HDL levels. The increase in BMI levels also had a corresponding 
decrease in serum HDL levels. 
             In the present study,  there was a significant positive correlation between serum 
total cholesterol and all other lipid parameters. 
           In the present study, there was a significant positive correlation between serum 
triglyceride levels and serum VLDL cholesterol levels. The increase in serum triglyceride 
levels also had a corresponding increase in serum VLDL cholesterol levels. 
            In the present study, there was no significant association between Total 
cholesterol, Triglycerides, LDL, VLDL  and BMI levels, smoking. 
           In the present study, there was no significant association between all lipid 
parameters  and  disease duration. 
 
 
 
 
                                        
 
                                          CONCLUSION 
 
                     The present study confirms that, circulating Hs-CRP levels are higher in 
COPD patients and may thus be regarded as a valid biomarker of low-grade systemic 
inflammation. 
                    The levels of Hs-CRP are significantly elevated in smokers with COPD, 
obese COPD patients and also correlates with the severity of the disease. 
                   This novel bio-marker is a valuable marker in staging and a predictor of 
COPD progression and management decision including administration of specific 
preventive and therapeutic strategies, potentially resulting in fewer morbidity and 
mortality. 
                 The present study confirms that, circulating Lipoprotein(a)  levels are higher in 
COPD patients may thus be regarded as a valid biomarker of atherothrombotic  acute 
events. The increase in serum lipoprotein(a) levels also had a corresponding increase 
serum total cholesterol and  LDL cholesterol levels. 
 
 
 
  
                   High serum Lipoprotein(a) level observed in this study  with high frequency 
of atherosclerotic disease such as coronary artery disease and cerebrovascular disease 
described in COPD patients. 
                  This novel bio-marker is a valuable marker for  predictor of atherothrombotic  
risk in COPD patients and management decision including administration of specific 
preventive and therapeutic strategies, potentially resulting in fewer morbidity and 
mortality. 
                 In the present study, there is no association between mean Lipoprotein(a) 
levels and the spirometry staging, BMI, smoking, disease duration. 
 
 
 
 
 
 
 
                                              
 
                                               SUMMARY 
 
                Serum High Sensitivity C-Reactive Protein is a marker of systemic 
inflammation and functional disability in COPD patients. 
                Increasing levels of Hs-CRP may means the infectious state in human body and 
can guide the clinical treatment of  COPD . 
               Serum Hs-CRP may be used as a simple auxiliary marker in staging and 
determining the prognosis of  COPD for early intervention. 
                Serum Lipoprotein(a) is a marker of atherosclerotic disease such as coronary 
artery disease and cerebrovascular diseas in COPD patients. 
               Serum Lipoprotein(a) may be used as a simple auxiliary marker in determining   
the   risk   of   atherosclerotic   disease   in   COPD  patients for early intervention. 
 
 
 
 
 
 
 
 
MASTER CHART - I CONTROL GROUP 
   
S
.N
O
 
A
G
E
 (
y
ea
rs
) 
S
E
X
 
B
M
I 
 k
g
/m
2
 
H
sC
R
P
 (
m
g
/L
) 
L
P
(a
) 
(m
g
/L
) 
T
O
T
A
L
 C
H
O
L
E
S
T
R
O
L
 (
m
g
/d
l)
 
T
R
IG
L
Y
C
E
R
ID
E
S
 (
m
g
/d
l)
 
H
D
L
-C
 (
m
g
/d
l)
 
L
D
L
-C
 (
m
g
/d
l)
 
V
L
D
L
-C
 (
m
g
/d
l)
 
G
L
U
C
O
S
E
 (
m
g
/d
l)
 
U
R
E
A
 (
m
g
/d
l)
 
C
R
E
A
T
IN
IN
E
 (
m
g
/d
l)
 
1 33 MALE 21.5 5 157 157 76 35 106.8 15.2 85 28 0.8 
2 52 MALE 34.8 6 146 175 91 42 114.8 18.2 97 19 0.6 
3 36 FEMALE 34.05 3 116 139 102 31 87.6 20.4 79 28 0.9 
4 54 MALE 22.6 5 112 140 109 41 77.2 21.8 92 28 0.7 
5 39 MALE 23.4 3 185 193 114 31 139.2 22.8 91 17 1.1 
6 47 MALE 27 3 185 149 76 31 102.8 15.2 87 38 0.7 
7 34 MALE 21.5 6 92 141 92 41 81.6 18.4 101 25 0.9 
8 43 FEMALE 27.8 4 171 191 86 49 124.8 17.2 108 33 1.2 
9 42 MALE 30.4 5 168 185 103 37 127.4 20.6 98 29 0.8 
10 29 FEMALE 34.2 6 96 180 101 39 120.8 20.2 84 20 0.9 
11 31 FEMALE 30.2 3 175 167 115 36 108 23 89 28 0.7 
12 31 FEMALE 24.2 3 98 191 107 37 132.6 21.4 94 34 1.1 
13 51 FEMALE 34.2 3 161 147 90 35 94 18 104 20 0.9 
14 44 MALE 21.2 2 190 167 94 32 116.2 18.8 80 28 0.8 
15 29 FEMALE 21.2 1 190 159 101 40 98.8 20.2 90 38 1.2 
16 48 FEMALE 21.2 1 105 195 110 53 120 22 82 25 0.6 
17 27 MALE 30.2 1 81 135 94 32 84.2 18.8 88 28 0.7 
18 70 MALE 21.7 3 157 161 86 31 112.8 17.2 85 28 0.8 
19 47 FEMALE 20 5 105 208 111 51 134.8 22.2 90 28 0.9 
20 48 MALE 21.3 2 157 183 117 46 113.6 23.4 92 22 0.7 
21 67 MALE 25.6 4 54 155 78 35 104.4 15.6 92 32 1.1 
22 57 FEMALE 22.6 5 185 192 87 44 130.6 17.4 89 28 0.7 
23 30 FEMALE 30.4 5 110 173 81 34 122.8 16.2 100 29 0.9 
24 58 MALE 20.8 1 130 165 77 36 113.6 15.4 83 35 0.8 
25 40 FEMALE 20.8 3 155 160 135 41 92 27 82 31 0.8 
26 65 MALE 26.9 4 147 187 105 34 132 21 102 38 0.7 
27 35 FEMALE 20.5 5 135 194 102 35 138.6 20.4 101 25 0.8 
28 62 MALE 32 2 175 171 76 39 116.8 15.2 99 29 1.2 
29 49 MALE 23.7 4 187 184 112 35 126.6 22.4 0.7 18 0.7 
30 45 MALE 30.2 2 172 169 87 33 118.6 17.4 84 38 0.6 
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1 33 MALE 21.5 5 157 157 76 35 106.8 15.2 85 28 0.8 
2 52 MALE 34.8 6 146 175 91 42 114.8 18.2 97 19 0.6 
3 36 FEMALE 34.05 3 116 139 102 31 87.6 20.4 79 28 0.9 
4 54 MALE 22.6 5 112 140 109 41 77.2 21.8 92 28 0.7 
5 39 MALE 23.4 3 185 193 114 31 139.2 22.8 91 17 1.1 
6 47 MALE 27 3 185 149 76 31 102.8 15.2 87 38 0.7 
7 34 MALE 21.5 6 92 141 92 41 81.6 18.4 101 25 0.9 
8 43 FEMALE 27.8 4 171 191 86 49 124.8 17.2 108 33 1.2 
9 42 MALE 30.4 5 168 185 103 37 127.4 20.6 98 29 0.8 
10 29 FEMALE 34.2 6 96 180 101 39 120.8 20.2 84 20 0.9 
11 31 FEMALE 30.2 3 175 167 115 36 108 23 89 28 0.7 
12 31 FEMALE 24.2 3 98 191 107 37 132.6 21.4 94 34 1.1 
13 51 FEMALE 34.2 3 161 147 90 35 94 18 104 20 0.9 
14 44 MALE 21.2 2 190 167 94 32 116.2 18.8 80 28 0.8 
15 29 FEMALE 21.2 1 190 159 101 40 98.8 20.2 90 38 1.2 
16 48 FEMALE 21.2 1 105 195 110 53 120 22 82 25 0.6 
17 27 MALE 30.2 1 81 135 94 32 84.2 18.8 88 28 0.7 
18 70 MALE 21.7 3 157 161 86 31 112.8 17.2 85 28 0.8 
19 47 FEMALE 20 5 105 208 111 51 134.8 22.2 90 28 0.9 
20 48 MALE 21.3 2 157 183 117 46 113.6 23.4 92 22 0.7 
21 67 MALE 25.6 4 54 155 78 35 104.4 15.6 92 32 1.1 
22 57 FEMALE 22.6 5 185 192 87 44 130.6 17.4 89 28 0.7 
23 30 FEMALE 30.4 5 110 173 81 34 122.8 16.2 100 29 0.9 
24 58 MALE 20.8 1 130 165 77 36 113.6 15.4 83 35 0.8 
25 40 FEMALE 20.8 3 155 160 135 41 92 27 82 31 0.8 
26 65 MALE 26.9 4 147 187 105 34 132 21 102 38 0.7 
27 35 FEMALE 20.5 5 135 194 102 35 138.6 20.4 101 25 0.8 
28 62 MALE 32 2 175 171 76 39 116.8 15.2 99 29 1.2 
29 49 MALE 23.7 4 187 184 112 35 126.6 22.4 0.7 18 0.7 
30 45 MALE 30.2 2 172 169 87 33 118.6 17.4 84 38 0.6 
 
 
 
                                        KEY TO MASTER CHART 
 
  
HsCRP -  high sensitivity C reactive protein 
 
LP(a) – Lipoprotein(a) 
 
HDL-c – High density lipoprotein cholesterol 
 
LDL-c - Low density lipoprotein cholesterol 
 
VLDL-c – Very  Low density lipoprotein cholesterol 
 
BMI – Body Mass Index 
 
P/Y – Pack years 
 
A- Absent 
 
P- Present 
 
                                      PROFORMA 
 
 
 
NAME:                                                                IP NO: 
AGE:                                                                   DOA: 
SEX:                                                                    SE CLASS:LOW/MIDDLE/HIGH 
ADDRESS: 
OCCUPATION: 
PRESENTING COMPLAINTS                          DURATION 
COUGH 
SPUTUM PRODUCTION 
DIFFICULTY IN BREATHING 
WHEEZE 
HEMOPTYSIS 
CHEST PAIN 
FEVER 
LEG SWELLING 
OTHERS (SPECIFY) 
RISK FACTORS & TRIGGERS: 
SMOKING 
AIR POLLUTION LIKE SMOKE/DUST 
RECURRENT URT 
ATOPY/ALLERGY 
SMOKING HISTORY: 
ACTIVE:                            CIGAR/CIGARETTE/BEEDI 
                                            AGE AT WHICH SMOKING STARTED 
                                            INTENSITY OF SMOKING IN PACK YEARS 
PASSIVE: 
                                            FATHER/HUSBAND/SON 
                                            HOUSE HOLD SMOKING 
                                            PACK YEARS OF SMOKING 
FAMILY HISTORY: 
BRONCHIAL ASTHMA/COPD 
OTHER DISEASES: 
PHT/SHT/DM/CAHD/VALVULAR HEART DISEASE/CONNECTIVE TISSUE 
DISEASE 
TREATMENT HISTORY 
GENERAL EXAMINATION 
ANAEMIA:                                                    PRESENT/ABSENT 
POLYCYTHEMIA:                                       PRESENT/ABSENT 
CYANOSIS:                                                   PRESENT/ABSENT 
PURSE LIP BREATHING:                           PRESENT/ABSENT 
USE OF ACCESSORY MUSCLES OF BREATHING:   PRESENT/ABSENT 
LYMPH NODE ENLARGEMENT:                                  PRESENT/ABSENT 
PEDAL EDEMA:                                                               PRESENT/ABSENT 
JUGULAR VENOUS PULSE: 
 VITALS: 
PR:       /MIN              BP:        mm/Hg                 RR:      /MIN 
SPO2:      %                TEMP:                               BMI: 
SYSTEMIC EXAMINATION 
CARDIO VASCULAR SYSTEM: 
 
CENTRAL NERVOUS SYSTEM: 
 
ABDOMINAL SYSYTEM: 
CONGESTIVE HEPATOMEGALY:          PRESENT/ABSENT 
RESPIRATORY SYSTEM: 
INSPECTION: 
 
PALPATION: 
 
PERCUSSION: 
 
AUSCULTATION: 
 
 
  
INVESTIGATIONS 
URINE R/E:      SUGAR               ALBUMIN                          DEPOSITS 
CBC:                 Hb                        ESR 
                          TC                        DC                                       PLATELETS 
FBS : 
SR.UREA : 
SR.CREATININE : 
ECG : 
CXR : 
Hs – CRP : 
LIPOPROTEIN(a)  :    
LIPID PROFILE :-  
TOTAL CHOLESTEROL : 
TGL : 
HDL-C : 
LDL-C : 
VLDL-C : 
 
 
 
  
SPIROMETRY: 
 
 
   GOLD STAGING              FEV 1            FEV1/FVC 
STAGE 1   
STAGE 2   
STAGE 3   
STAGE 4   
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